|
Glioblastoma Multiforme
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Consistent with this, we found that NLK expression is especially low in a subset of GBMs that harbors high WNT/mesenchymal activities.
|
26023737 |
2015 |
|
Glioblastoma Multiforme
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Subarachnoid Hemorrhage
|
0.200 |
ModifyingMutation
|
disease |
RGD |
Expression of Nemo-like kinase (NLK) in the brain in a rat experimental subarachnoid hemorrhage model.
|
23325309 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we report that Nemo-like kinase (NLK) boosts cell cycle progression, which facilitates tumor development by releasing the E2F1 protein from HDAC1.
|
29803790 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-362-3p targets nemo-like kinase and functions as a tumor suppressor in renal cancer cells.
|
26647877 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with NLK short hairpin RNA significantly reduced SCLC tumor growth in vivo.
|
27895463 |
2016 |
|
Unipolar Depression
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
Mood Disorders
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
Major Depressive Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data unravel a tumor suppressive role of NLK and support the feasibility of combining oncogenomics with in vivo RNAi screen.
|
26023737 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we focused on the clinical significance of NLK in HCC and found that high expression of NLK was significantly associated with Edmondson-Steiner grade (P = 0.002), tumor size (P = 0.022), and no. of tumor nodules (P < 0.001), and NLK was positively correlated with proliferation marker Ki-67 (P < 0.01).
|
26022162 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also found that NLK was involved in miR-92b-induced cell proliferation, and its protein level was obviously downregulated in the miR-92b-overexpressing xenograft tumors.
|
26503628 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with NLK‑positive tumors demonstrated higher rates of recurrence and mortality than patients with NLK‑negative tumors.
|
25371216 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, both NLK knockdown and metformin treatment reduced the tumor sphere formation capacity and percentage of CD133+ cells.
|
26503334 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NLK is gradually considered as a potential tumor suppressor or an oncogene depending on the tumor system, and silencing or upregulating of NLK may provide an effective therapeutic approach against tumors.
|
26427665 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All these results suggested that NLK was an identified miR-199a-3p target gene and functioned as a tumor suppressor gene in colorectal cancer.
|
24972723 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although, NLK is known to be a tumor suppressor in Wnt/beta-catenin signaling pathway of colon cancer, the other events occurring downstream of NLK pathways in other types of cancer remain unclear.
|
20512928 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since NLK may be a tumor suppressor as a negative regulator of Wnt/beta-catenin pathway, we established tetracycline-inducible NLK and its kinase-negative mutant expression in DLD-1 human colon cancer cells to analyze the effect of NLK on cell growth and viability.
|
12901858 |
2003 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
The down-regulation of NLK expression may play a role in the proliferation, apoptosis, and invasion of laryngeal carcinoma cells and it is possible by regulating MMP-9 and CDCP1 expression.
|
31364124 |
2019 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Additionally, proliferation, colony formation, and invasion turned out to be enhanced in NLK-overexpressing cells.
|
30451112 |
2019 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
In vitro, NLK overexpression inhibited A549 ncell migration and invasion as determined by wound healing and Transwell migration assays, respectively.
|
31322229 |
2019 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
NLK overexpression significantly correlated with higher histological grade (<i>P</i>=0.001), vascular/lymphatic invasion (<i>P</i>=0.010), lymph node metastasis (<i>P</i>=0.012), and recurrence (<i>P</i>=0.022).
|
29445289 |
2018 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
A reporter assay showed increased luciferase activity in NLK knockdown glioma cells and transcriptional activity of β-cantenin/TCF was remarkably enhanced, which further confirmed that NLK antagonizes Wnt signaling-mediated anchorage-dependent and independent cell proliferation and invasion.
|
27583705 |
2017 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
NLK expression was found to be significantly higher in CRC tissues as well as associated with the depth of tumor invasion, lymph node metastasis, distant metastasis, histological differentiation, vascular invasion and advanced tumor stage.
|
25371216 |
2015 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
In vitro, we also found that NLK suppressed the biological behaviors of colorectal cancer cells, including the abilities of cell proliferation, clone formation, wound healing, migration and invasion (P<0.05), while overexpression of NLK increased the apoptotic rate of colorectal cancer cells.
|
24972723 |
2014 |